A very strong adverse effect on RFS (p = 0.0001) was seen with TGFB3 (Fig. 9c, d), in line with the central role of the associated signaling pathways in cancer, and with PTGER3 (Fig. 9c, e; p <0.0001), encoding a prostaglandin E2 receptor (Fig. 6b). Here, PTGER3 is linked to cancer.